Tipiracil

CHEMBL235668 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
242.7 g/mol
LogP
-0.7
Phase
4

Tipiracil is a thymidine phosphorylase inhibitor that blocks the enzymatic degradation of trifluridine (TAS-102 combination partner) in the gut and blood, maintaining therapeutic trifluridine plasma concentrations. When combined with trifluridine, it enables sufficient systemic trifluridine exposure to incorporate into tumor cell DNA and inhibit thymidylate synthase, exerting cytotoxic effects. The combination is approved for refractory metastatic colorectal cancer and gastric cancer.

分子量

242.6600 g/mol

LogP

-0.70

TPSA

85.30 Ų

リピンスキーの五則

適合

治療領域

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

N=C1CCCN1Cc1[nH]c(=O)[nH]c(=O)c1Cl

InChI

InChI=1S/C9H11ClN4O2/c10-7-5(12-9(16)13-8(7)15)4-14-3-1-2-6(14)11/h11H,1-4H2,(H2,12,13,15,16)

Molecular Formula

C9H11ClN4O2

HBD / HBA

3 / 3

回転可能結合数

2

重原子数

16

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

Tipiracil is a thymidine phosphorylase inhibitor that blocks the enzymatic degradation of trifluridine (TAS-102 combination partner) in the gut and blood, maintaining therapeutic trifluridine plasma concentrations. When combined with trifluridine, it enables sufficient systemic trifluridine exposure to incorporate into tumor cell DNA and inhibit thymidylate synthase, exerting cytotoxic effects. The combination is approved for refractory metastatic colorectal cancer and gastric cancer.

Yes, Tipiracil is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL235668. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6323266. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.